In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals

Translational Neurodegeneration

Volumn 3, Issue 1, 2014, Pages

  Zimmer, Eduardo R ^a,b,c   Leuzy, Antoine ^a,b   Bhat, Venkat ^d   Gauthier, Serge ^a   Rosa Neto, Pedro ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Positron emission tomography; Tau molecular agents; Tau rodent models; Tauopathies

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; MICROTUBULE ASSOCIATED PROTEIN; TAU PROTEIN; TRACER;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; DISEASE COURSE; FRONTOTEMPORAL DEMENTIA; HUMAN; IN VIVO STUDY; MOLECULAR IMAGING; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; TAUOPATHY; THEORETICAL MODEL;

EID: 84899150245     PISSN: None     EISSN: 20479158     Source Type: Journal    
DOI: 10.1186/2047-9158-3-6     Document Type: Review

References (39)

1. Williams DR. Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau. Int Med J 2006, 36:652-660.
2. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000, 33:95-130. 10.1016/S0165-0173(00)00019-9, 10967355.
3. Gendreau KL, Hall GF. Tangles, toxicity, and tau secretion in AD - New approaches to a vexing problem. Frontiers in Neurol 2013, 4:160.
4. Johnson GV, Stoothoff WH. Tau phosphorylation in neuronal cell function and dysfunction. J of cell Sci 2004, 117:5721-5729.
5. Gong CX, Iqbal K. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Current Med Chem 2008, 15:2321-2328.
6. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathologica 2002, 103:26-35. 10.1007/s004010100423, 11837744.
7. Spires-Jones TL, Stoothoff WH, de Calignon A, Jones PB, Hyman BT. Tau pathophysiology in neurodegeneration: a tangled issue. Trends in Neurosci 2009, 32:150-159.
8. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE, Ince PG, Kamphorst W, Revesz T, Rozemuller AJ, Kumar-Singh S, Akiyama H, Baborie A, Spina S, Dickson DW, Trojanowski JQ, Mann DM. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathologica 2010, 119:1-4. 10.1007/s00401-009-0612-2, 2799633, 19924424.
9. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007, 8:663-672.
10. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica 1991, 82:239-259. 10.1007/BF00308809, 1759558.
11. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992, 42:631-639. 10.1212/WNL.42.3.631, 1549228.
12. Hampel H, Burger K, Pruessner JC, Zinkowski R, DeBernardis J, Kerkman D, Leinsinger G, Evans AC, Davies P, Moller HJ, Teipel SJ. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Archives of Neurol 2005, 62:770-773.
13. Guillozet AL, Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Archives of Neurol 2003, 60:729-736.
14. Kouri N, Whitwell JL, Josephs KA, Rademakers R, Dickson DW. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol 2011, 7:263-272. 10.1038/nrneurol.2011.43, 21487420.
15. Gotz J, Deters N, Doldissen A, Bokhari L, Ke Y, Wiesner A, Schonrock N, Ittner LM. A decade of tau transgenic animal models and beyond. Brain Pathol 2007, 17:91-103. 10.1111/j.1750-3639.2007.00051.x, 17493043.
16. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science 2006, 314:777-781. 10.1126/science.1132814, 17082447.
17. Platt TL, Reeves VL, Murphy MP. Transgenic models of Alzheimer's disease: better utilization of existing models through viral transgenesis. Biochimica et biophysica Acta 1832, 2013:1437-1448.
18. Nasreddine ZS, Loginov M, Clark LN, Lamarche J, Miller BL, Lamontagne A, Zhukareva V, Lee VM, Wilhelmsen KC, Geschwind DH. From genotype to phenotype: a clinical pathological, and biochemical investigation of frontotemporal dementia and parkinsonism (FTDP-17) caused by the P301L tau mutation. Annals of Neurol 1999, 45:704-715.
19. Zilka N, Filipcik P, Koson P, Fialova L, Skrabana R, Zilkova M, Rolkova G, Kontsekova E, Novak M. Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett 2006, 580:3582-3588. 10.1016/j.febslet.2006.05.029, 16753151.
20. Umeda T, Maekawa S, Kimura T, Takashima A, Tomiyama T, Mori H. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice. Acta Neuropathol 2014, In press.
21. de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 2012, 73:685-697. 10.1016/j.neuron.2011.11.033, 3292759, 22365544.
22. Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. The J of Neurosci: the Off J of the Soc for Neurosci 2013, 33:1024-1037.
23. Ahlijanian MK, Barrezueta NX, Williams RD, Jakowski A, Kowsz KP, McCarthy S, Coskran T, Carlo A, Seymour PA, Burkhardt JE, Nelson RB, McNeish JD. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci U S A 2000, 97:2910-2915. 10.1073/pnas.040577797, 16029, 10706614.
24. Bian F, Nath R, Sobocinski G, Booher RN, Lipinski WJ, Callahan MJ, Pack A, Wang KK, Walker LC. Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice. The J of comparative Neurol 2002, 446:257-266.
25. Zimmer ER, Kalinine E, Haas CB, Torrez VR, Souza DO, Muller AP, Portela LV. Pretreatment with memantine prevents Alzheimer-like alterations induced by intrahippocampal okadaic acid administration in rats. Curr Alzheimer Res 2012, 9:1182-1190. 10.2174/156720512804142877, 22515493.
26. Grunblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J of Neurochem 2007, 101:757-770.
27. Van der Jeugd A, Vermaercke B, Derisbourg M, Lo AC, Hamdane M, Blum D, Buee L, D'Hooge R. Progressive age-related cognitive decline in tau mice. J of Alzheimer's Dis: JAD 2013, 37:777-788.
28. Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. The J of Neurosci: the Off J of the Soc for Neurosci 2010, 30:16559-16566.
29. Carreras I, McKee AC, Choi JK, Aytan N, Kowall NW, Jenkins BG, Dedeoglu A. R-flurbiprofen improves tau, but not Ass pathology in a triple transgenic model of Alzheimer's disease. Brain Res 2013, 1541:115-127.
30. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J of Alzheimer's Dis: JAD 2013, 34:457-468.
31. Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, Shankle WR, Lerner AJ, Su MY, Elizarov A, Kolb HC. Early clinical PET imaging results with the novel PHF-Tau radioligand [F18]-T808. J of Alzheimer's Dis: JAD 2014, 38:171-184.
32. Harada R, Okamura N, Furumoto S, Tago T, Maruyama M, Higuchi M, Yoshikawa T, Arai H, Iwata R, Kudo Y, Yanai K. Comparison of the binding characteristics of [18 F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology. European J of nuclear Med and Mole imaging 2013, 40:125-132.
33. Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor AR, McLean CA, Cao D, Rigopoulos A, Cartwright GA, O'Keefe G, Gong S, Adlard PA, Barnham KJ, Rowe CC, Masters CL, Kudo Y, Cappai R, Yanai K, Villemagne VL. 18 F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain J Neurol 2011, 134:1089-1100.
34. Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, Mulligan RS, Villemagne VL, Akatsu H, Yamamoto T, Arai H, Iwata R, Yanai K, Kudo Y. Novel 18 F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nuclear Med 2013, 54:1420-1427.
35. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang MR, Trojanowski JQ, Lee VM, Ono M, Masamoto K, Takano H, Sahara N, Iwata N, Okamura N, Furumoto S, Kudo Y, Chang Q, Saido TC, Takashima A, Lewis J, Jang MK, Aoki I, Ito H, Higuchi M. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013, 79:1094-1108. 10.1016/j.neuron.2013.07.037, 24050400.
36. Bunsey M, Eichenbaum H. Conservation of hippocampal memory function in rats and humans. Nature 1996, 379:255-257. 10.1038/379255a0, 8538790.
37. Hurtado DE, Molina-Porcel L, Iba M, Aboagye AK, Paul SM, Trojanowski JQ, Lee VM. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. The Am J of Pathol 1977-1988, 2010:177.
38. Vogt BA, Paxinos G. Cytoarchitecture of mouse and rat cingulate cortex with human homologies. Brain Struct Funct 2014, 219:185-192. 10.1007/s00429-012-0493-3, 23229151.
39. Giacobini E, Gold G. Alzheimer disease therapy-moving from amyloid-beta to tau. Nature Rev Neurol 2013, 9:677-686.